Helixor

aqueous extract from Viscum album from fir, pine and apple trees that activates natural killer cytotoxicity against K562 tumor cells; it contains lectins, viscotoxins, alkaloids; Helixor-M contains a dialysable oligosaccharide (HM-BP) that activates natural killer (NK) cytotoxicity against K562 tumour cells

Also Known As:

Networked: 11 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Axtner, Jan: 2 articles (03/2015 - 01/2014)
2.	Happe, Antje: 2 articles (03/2015 - 01/2014)
3.	Kröz, Matthias: 2 articles (03/2015 - 01/2014)
4.	Matthes, Harald: 2 articles (03/2015 - 01/2014)
5.	Schad, Friedemann: 2 articles (03/2015 - 01/2014)
6.	Steele, Megan L: 2 articles (03/2015 - 01/2014)
7.	Jung, Ina: 1 article (05/2019)
8.	Kang, Du-Young: 1 article (05/2019)
9.	Koo, Dong-Hoe: 1 article (05/2019)
10.	Lee, Seung-Sei: 1 article (05/2019)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2008 - "Complementary treatment with the sME HELIXOR proved to be beneficial for breast cancer patients since it significantly improved quality of life and significantly reduced persistant signs/symptoms of the disease/treatment during the validated aftercare period of approximately five years." 01/01/2008 - "To investigate the safety and efficacy of complementary treatment of breast cancer patients with the standardized mistletoe extract (sME) HELIXOR in routine practice during aftercare through a multicenter comparative epidemiological cohort study with 53 randomly selected hospitals/practices representatively distributed in Germany, including oncologists, gynaecologists and general practitioners. "
2.	Neoplasms (Cancer) 01/01/2007 - "Helixor mistletoe preparations and ML-1 have cytotoxic activity and do not stimulate tumor cell proliferation in vitro which is in accordance with previous scientifically based observations on aqueous mistletoe extracts." 03/06/1990 - "In addition, Helixor supposedly bridges the dramatic gap between conventional and natural treatment of cancer in that it exerts both a selective cancerostatic and an immunostimulatory effect. " 01/01/2023 - "Patients with solid tumor progressing on at least one line of chemotherapy received escalating doses of Helixor M three times a week. " 03/01/2015 - "A total of 123 cancer patients received 862 IT mistletoe injections (preparations from Abnoba, Helixor and Iscucin). " 03/06/1990 - "[Helixor--mistletoe preparation for cancer therapy. "
3.	Malignant Pleural Effusion 04/01/1997 - "In a recent study, 20 consecutive cancer patients with malignant pleural effusions were treated intrapleurally with the mistletoe extract Helixor. " 05/01/2019 - "Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer."
4.	Hypersensitivity (Allergy) 05/26/1999 - "In conclusion, our study provide evidence that adverse effects towards VAL (Helixor) are seldom and are dominated by an application site reaction suggesting the involvement of delayed type hypersensitivity (DTH) reactions."
5.	Leukemia 03/01/1986 - "The in vitro effectiveness of three Helixor preparations produced from mistletoes of different host trees on suspension cell cultures of the human leukemia cell line Molt 4 has been compared by means of dose-response investigations. " 03/06/1990 - "Helixor was developed by the Section for Leukemia and Cancer Therapy of the Gemein-schaft Fischermühle e. "

Related Drugs and Biologics

1.	Cytokines
2.	Interleukin-6 (Interleukin 6)
3.	Suspensions
4.	Interleukin-1 (Interleukin 1)
5.	Doxorubicin (Adriamycin)
6.	abnoba viscum
7.	viscum album peptide (Iscador)

Related Therapies and Procedures

1.	Pleurodesis
2.	Therapeutics
3.	Injections
4.	Intravenous Infusions
5.	Drug Therapy (Chemotherapy)